Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2011-07-28

AUTHORS

Hiroshi Hasegawa, Hiroyuki Takano, Hiroya Narumi, Masashi Ohtsuka, Tadahiko Mizuguchi, Takao Namiki, Yoshio Kobayashi, Issei Komuro

ABSTRACT

The Telmisartan and Losartan Cardiac Evaluation Trial, a multicenter, prospective, randomized, open-labeled, blinded-endpoint trial, was designed to compare the effects of two angiotensin II receptor blockers (ARBs), telmisartan and losartan, on cardiovascular protection in Japanese patients with mild to moderate essential hypertension. We compared the effects of telmisartan and losartan on left ventricular (LV) hypertrophy, cardiac function, atherosclerosis of carotid arteries and surrogate markers related to the actions of peroxisome proliferator-activated receptor-γ. A total of 58 patients were enrolled in the present trial and the follow-up period was 1 year. There were no significant differences in blood pressure (BP) levels between the telmisartan group and the losartan group throughout the trial. The percentage of the patients treated with ARB monotherapy was significantly higher in the telmisartan group compared with the losartan group. In addition, the progression of intima-media thickness of common carotid artery was significantly inhibited in the telmisartan group compared with the losartan group. Neither group experienced significant changes in cardiac function and LV mass index. There were no differences between the groups with respect to changes in surrogate markers such as serum adiponectin, creatinine, homeostasis model assessment index, plasminogen activator inhibitor-1 and high sensitivity C-reactive protein. Although BP levels were equal and well controlled in both groups, telmisartan showed more protective vascular effects than losartan. More... »

PAGES

1179-1184

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/hr.2011.114

DOI

http://dx.doi.org/10.1038/hr.2011.114

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1040467790

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/21796128


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiotensin II Type 1 Receptor Blockers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Atherosclerosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzimidazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzoates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cardiovascular Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carotid Intima-Media Thickness", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart Ventricles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertension", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertrophy, Left Ventricular", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Japan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Losartan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Severity of Illness Index", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Single-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Telmisartan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hasegawa", 
        "givenName": "Hiroshi", 
        "id": "sg:person.01371272633.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01371272633.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takano", 
        "givenName": "Hiroyuki", 
        "id": "sg:person.0624235222.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624235222.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Narumi", 
        "givenName": "Hiroya", 
        "id": "sg:person.01203207133.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203207133.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, Seirei Yokohama Hospital, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Cardiovascular Medicine, Seirei Yokohama Hospital, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ohtsuka", 
        "givenName": "Masashi", 
        "id": "sg:person.01075476751.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075476751.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, Chiba Social Insurance Hospital, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Cardiovascular Medicine, Chiba Social Insurance Hospital, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mizuguchi", 
        "givenName": "Tadahiko", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Frontier Japanese-Oriental \u2018Kampo\u2019 medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Frontier Japanese-Oriental \u2018Kampo\u2019 medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Namiki", 
        "givenName": "Takao", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kobayashi", 
        "givenName": "Yoshio", 
        "id": "sg:person.016657042642.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016657042642.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136593.b", 
          "name": [
            "Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Komuro", 
        "givenName": "Issei", 
        "id": "sg:person.01012024207.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012024207.33"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/hr.2009.131", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008963088", 
          "https://doi.org/10.1038/hr.2009.131"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/hr.2009.34", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047258719", 
          "https://doi.org/10.1038/hr.2009.34"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1475-2840-4-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018238203", 
          "https://doi.org/10.1186/1475-2840-4-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1291/hypres.28.917", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045343815", 
          "https://doi.org/10.1291/hypres.28.917"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1291/hypres.30.49", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010521145", 
          "https://doi.org/10.1291/hypres.30.49"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1291/hypres.28.203", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026569557", 
          "https://doi.org/10.1291/hypres.28.203"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11906-005-0019-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033309130", 
          "https://doi.org/10.1007/s11906-005-0019-y"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-07-28", 
    "datePublishedReg": "2011-07-28", 
    "description": "The Telmisartan and Losartan Cardiac Evaluation Trial, a multicenter, prospective, randomized, open-labeled, blinded-endpoint trial, was designed to compare the effects of two angiotensin II receptor blockers (ARBs), telmisartan and losartan, on cardiovascular protection in Japanese patients with mild to moderate essential hypertension. We compared the effects of telmisartan and losartan on left ventricular (LV) hypertrophy, cardiac function, atherosclerosis of carotid arteries and surrogate markers related to the actions of peroxisome proliferator-activated receptor-\u03b3. A total of 58 patients were enrolled in the present trial and the follow-up period was 1 year. There were no significant differences in blood pressure (BP) levels between the telmisartan group and the losartan group throughout the trial. The percentage of the patients treated with ARB monotherapy was significantly higher in the telmisartan group compared with the losartan group. In addition, the progression of intima-media thickness of common carotid artery was significantly inhibited in the telmisartan group compared with the losartan group. Neither group experienced significant changes in cardiac function and LV mass index. There were no differences between the groups with respect to changes in surrogate markers such as serum adiponectin, creatinine, homeostasis model assessment index, plasminogen activator inhibitor-1 and high sensitivity C-reactive protein. Although BP levels were equal and well controlled in both groups, telmisartan showed more protective vascular effects than losartan.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/hr.2011.114", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1313717", 
        "issn": [
          "0916-9636", 
          "1348-4214"
        ], 
        "name": "Hypertension Research", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "11", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "34"
      }
    ], 
    "keywords": [
      "angiotensin II receptor blockers", 
      "effects of telmisartan", 
      "telmisartan group", 
      "losartan group", 
      "cardiovascular protection", 
      "cardiac function", 
      "surrogate marker", 
      "carotid artery", 
      "homeostasis model assessment index", 
      "blinded-endpoint trial", 
      "moderate essential hypertension", 
      "peroxisome proliferator-activated receptor", 
      "II receptor blockers", 
      "LV mass index", 
      "model assessment index", 
      "high sensitivity C", 
      "Japanese hypertensive patients", 
      "blood pressure levels", 
      "left ventricular hypertrophy", 
      "intima-media thickness", 
      "protective vascular effects", 
      "plasminogen activator inhibitor-1", 
      "common carotid artery", 
      "proliferator-activated receptor", 
      "activator inhibitor-1", 
      "ARB monotherapy", 
      "hypertensive patients", 
      "receptor blockers", 
      "serum adiponectin", 
      "sensitivity C", 
      "vascular effects", 
      "essential hypertension", 
      "ventricular hypertrophy", 
      "BP levels", 
      "mass index", 
      "reactive protein", 
      "Japanese patients", 
      "losartan", 
      "present trial", 
      "patients", 
      "telmisartan", 
      "inhibitor-1", 
      "trials", 
      "significant differences", 
      "artery", 
      "significant changes", 
      "group", 
      "pressure levels", 
      "evaluation trials", 
      "markers", 
      "assessment index", 
      "multicenter", 
      "monotherapy", 
      "hypertension", 
      "adiponectin", 
      "atherosclerosis", 
      "creatinine", 
      "blockers", 
      "hypertrophy", 
      "progression", 
      "receptors", 
      "index", 
      "effect", 
      "levels", 
      "differences", 
      "total", 
      "protection", 
      "changes", 
      "years", 
      "percentage", 
      "function", 
      "period", 
      "protein", 
      "action", 
      "addition", 
      "respect", 
      "thickness", 
      "Losartan Cardiac Evaluation Trial", 
      "Cardiac Evaluation Trial"
    ], 
    "name": "Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients", 
    "pagination": "1179-1184", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1040467790"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/hr.2011.114"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "21796128"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/hr.2011.114", 
      "https://app.dimensions.ai/details/publication/pub.1040467790"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_533.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/hr.2011.114"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/hr.2011.114'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/hr.2011.114'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/hr.2011.114'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/hr.2011.114'


 

This table displays all metadata directly associated to this object as RDF triples.

322 TRIPLES      22 PREDICATES      136 URIs      121 LITERALS      31 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/hr.2011.114 schema:about N038ede963c5b41c1bc8d02a1b7627b82
2 N10e78a6a136446348b4add41d752f1e9
3 N34d2338168814f9fb1b892303169c3b3
4 N3713e18e4e0c458693cab01b1bc7a40f
5 N44789197a8044c2ea915e02dac5aea44
6 N45928facd6f04ffcba264ab672474aa2
7 N573197926f6648b2b37d2aec1668d87a
8 N5c98fa296be445aebae7a8c9d83d3e4b
9 N63deb11e8fe841e2832a33de02568d47
10 N685747f78ae94942acc8d3844b7e9693
11 N6897187a4c1a45b79b55a6da379fad36
12 N99f786711d664ecfbeb0a3c52e363d7f
13 N9ff17e4476144949aaa05663c6f4dcf7
14 Na2367774f51a430cbf87118de1f82564
15 Na38ed7e400414f46b92271d8cf56c2e2
16 Na997319ba6094f62989cf946dcc6ce7a
17 Nb63a3cf599e748028ac77ee71627687f
18 Nb6a4d36eecfc4d6683c4ffaa0d7abb26
19 Nbdceaebe451d4815b43aa2f21c0ee0ad
20 Nc75ec5ebeb0b4a4aa446a18d11033abe
21 Ncaa25ba3ec314ef19d876d5f003e5b82
22 Nd00be27ee99b4213bec7529aabc14de0
23 Ndb522d06e08043a5b5421f6e54fb8cbf
24 Ne0ecc0f969fa4123a4aa200daf214610
25 anzsrc-for:11
26 anzsrc-for:1102
27 schema:author N58899e8f3a084f3498bae15774f8fcb8
28 schema:citation sg:pub.10.1007/s11906-005-0019-y
29 sg:pub.10.1038/hr.2009.131
30 sg:pub.10.1038/hr.2009.34
31 sg:pub.10.1186/1475-2840-4-6
32 sg:pub.10.1291/hypres.28.203
33 sg:pub.10.1291/hypres.28.917
34 sg:pub.10.1291/hypres.30.49
35 schema:datePublished 2011-07-28
36 schema:datePublishedReg 2011-07-28
37 schema:description The Telmisartan and Losartan Cardiac Evaluation Trial, a multicenter, prospective, randomized, open-labeled, blinded-endpoint trial, was designed to compare the effects of two angiotensin II receptor blockers (ARBs), telmisartan and losartan, on cardiovascular protection in Japanese patients with mild to moderate essential hypertension. We compared the effects of telmisartan and losartan on left ventricular (LV) hypertrophy, cardiac function, atherosclerosis of carotid arteries and surrogate markers related to the actions of peroxisome proliferator-activated receptor-γ. A total of 58 patients were enrolled in the present trial and the follow-up period was 1 year. There were no significant differences in blood pressure (BP) levels between the telmisartan group and the losartan group throughout the trial. The percentage of the patients treated with ARB monotherapy was significantly higher in the telmisartan group compared with the losartan group. In addition, the progression of intima-media thickness of common carotid artery was significantly inhibited in the telmisartan group compared with the losartan group. Neither group experienced significant changes in cardiac function and LV mass index. There were no differences between the groups with respect to changes in surrogate markers such as serum adiponectin, creatinine, homeostasis model assessment index, plasminogen activator inhibitor-1 and high sensitivity C-reactive protein. Although BP levels were equal and well controlled in both groups, telmisartan showed more protective vascular effects than losartan.
38 schema:genre article
39 schema:inLanguage en
40 schema:isAccessibleForFree true
41 schema:isPartOf Nc497f9707f4c4f27b8abfbe6f5f75ae1
42 Nf86ee18df29b4993bcc368556c538484
43 sg:journal.1313717
44 schema:keywords ARB monotherapy
45 BP levels
46 Cardiac Evaluation Trial
47 II receptor blockers
48 Japanese hypertensive patients
49 Japanese patients
50 LV mass index
51 Losartan Cardiac Evaluation Trial
52 action
53 activator inhibitor-1
54 addition
55 adiponectin
56 angiotensin II receptor blockers
57 artery
58 assessment index
59 atherosclerosis
60 blinded-endpoint trial
61 blockers
62 blood pressure levels
63 cardiac function
64 cardiovascular protection
65 carotid artery
66 changes
67 common carotid artery
68 creatinine
69 differences
70 effect
71 effects of telmisartan
72 essential hypertension
73 evaluation trials
74 function
75 group
76 high sensitivity C
77 homeostasis model assessment index
78 hypertension
79 hypertensive patients
80 hypertrophy
81 index
82 inhibitor-1
83 intima-media thickness
84 left ventricular hypertrophy
85 levels
86 losartan
87 losartan group
88 markers
89 mass index
90 model assessment index
91 moderate essential hypertension
92 monotherapy
93 multicenter
94 patients
95 percentage
96 period
97 peroxisome proliferator-activated receptor
98 plasminogen activator inhibitor-1
99 present trial
100 pressure levels
101 progression
102 proliferator-activated receptor
103 protection
104 protective vascular effects
105 protein
106 reactive protein
107 receptor blockers
108 receptors
109 respect
110 sensitivity C
111 serum adiponectin
112 significant changes
113 significant differences
114 surrogate marker
115 telmisartan
116 telmisartan group
117 thickness
118 total
119 trials
120 vascular effects
121 ventricular hypertrophy
122 years
123 schema:name Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients
124 schema:pagination 1179-1184
125 schema:productId N389d816049414e09b7f8235ca7704d7b
126 N472b22301a6e4e329a579e0ab5a61b0f
127 Nf019ecb8bd51455687f3d972da017254
128 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040467790
129 https://doi.org/10.1038/hr.2011.114
130 schema:sdDatePublished 2022-01-01T18:24
131 schema:sdLicense https://scigraph.springernature.com/explorer/license/
132 schema:sdPublisher N30caa2497aeb4c0eb95d7ae3b2b15dbb
133 schema:url https://doi.org/10.1038/hr.2011.114
134 sgo:license sg:explorer/license/
135 sgo:sdDataset articles
136 rdf:type schema:ScholarlyArticle
137 N038ede963c5b41c1bc8d02a1b7627b82 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Telmisartan
139 rdf:type schema:DefinedTerm
140 N10e78a6a136446348b4add41d752f1e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Middle Aged
142 rdf:type schema:DefinedTerm
143 N1f35a6910630489ebaf73e62ce1b9bff rdf:first sg:person.01203207133.99
144 rdf:rest N7d6d69e2aa0b463881d4b040a79fecc1
145 N30caa2497aeb4c0eb95d7ae3b2b15dbb schema:name Springer Nature - SN SciGraph project
146 rdf:type schema:Organization
147 N34d2338168814f9fb1b892303169c3b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Hypertrophy, Left Ventricular
149 rdf:type schema:DefinedTerm
150 N3713e18e4e0c458693cab01b1bc7a40f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Follow-Up Studies
152 rdf:type schema:DefinedTerm
153 N389d816049414e09b7f8235ca7704d7b schema:name dimensions_id
154 schema:value pub.1040467790
155 rdf:type schema:PropertyValue
156 N44789197a8044c2ea915e02dac5aea44 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Aged
158 rdf:type schema:DefinedTerm
159 N45928facd6f04ffcba264ab672474aa2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Japan
161 rdf:type schema:DefinedTerm
162 N472b22301a6e4e329a579e0ab5a61b0f schema:name pubmed_id
163 schema:value 21796128
164 rdf:type schema:PropertyValue
165 N4936ccfa3a534ef4b6a4a442e9721ee8 schema:affiliation grid-institutes:grid.136304.3
166 schema:familyName Namiki
167 schema:givenName Takao
168 rdf:type schema:Person
169 N573197926f6648b2b37d2aec1668d87a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Angiotensin II Type 1 Receptor Blockers
171 rdf:type schema:DefinedTerm
172 N58899e8f3a084f3498bae15774f8fcb8 rdf:first sg:person.01371272633.17
173 rdf:rest Nfab3a4530a6c43ac84c50403d1b200e1
174 N5c98fa296be445aebae7a8c9d83d3e4b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Risk Factors
176 rdf:type schema:DefinedTerm
177 N5cbc9fd97ac74413998c335f6ea95773 schema:affiliation grid-institutes:None
178 schema:familyName Mizuguchi
179 schema:givenName Tadahiko
180 rdf:type schema:Person
181 N63deb11e8fe841e2832a33de02568d47 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Benzimidazoles
183 rdf:type schema:DefinedTerm
184 N685747f78ae94942acc8d3844b7e9693 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Severity of Illness Index
186 rdf:type schema:DefinedTerm
187 N6897187a4c1a45b79b55a6da379fad36 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Heart Ventricles
189 rdf:type schema:DefinedTerm
190 N6ab5f61b71654c5b86f28c5383317e42 rdf:first N4936ccfa3a534ef4b6a4a442e9721ee8
191 rdf:rest N8d12ab1e2d864a1084a6fdeee905c4a8
192 N72e67d5ae4b14ebfb9d95b8c5c432a42 rdf:first sg:person.01012024207.33
193 rdf:rest rdf:nil
194 N7d6d69e2aa0b463881d4b040a79fecc1 rdf:first sg:person.01075476751.12
195 rdf:rest Ndb9a8665de71427fae03986030df8a85
196 N8d12ab1e2d864a1084a6fdeee905c4a8 rdf:first sg:person.016657042642.17
197 rdf:rest N72e67d5ae4b14ebfb9d95b8c5c432a42
198 N99f786711d664ecfbeb0a3c52e363d7f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Benzoates
200 rdf:type schema:DefinedTerm
201 N9ff17e4476144949aaa05663c6f4dcf7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Adult
203 rdf:type schema:DefinedTerm
204 Na2367774f51a430cbf87118de1f82564 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Carotid Intima-Media Thickness
206 rdf:type schema:DefinedTerm
207 Na38ed7e400414f46b92271d8cf56c2e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Cardiovascular Diseases
209 rdf:type schema:DefinedTerm
210 Na997319ba6094f62989cf946dcc6ce7a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
211 schema:name Humans
212 rdf:type schema:DefinedTerm
213 Nb63a3cf599e748028ac77ee71627687f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
214 schema:name Atherosclerosis
215 rdf:type schema:DefinedTerm
216 Nb6a4d36eecfc4d6683c4ffaa0d7abb26 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
217 schema:name Treatment Outcome
218 rdf:type schema:DefinedTerm
219 Nbdceaebe451d4815b43aa2f21c0ee0ad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
220 schema:name Male
221 rdf:type schema:DefinedTerm
222 Nc497f9707f4c4f27b8abfbe6f5f75ae1 schema:issueNumber 11
223 rdf:type schema:PublicationIssue
224 Nc75ec5ebeb0b4a4aa446a18d11033abe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
225 schema:name Prospective Studies
226 rdf:type schema:DefinedTerm
227 Ncaa25ba3ec314ef19d876d5f003e5b82 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
228 schema:name Losartan
229 rdf:type schema:DefinedTerm
230 Nd00be27ee99b4213bec7529aabc14de0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
231 schema:name Single-Blind Method
232 rdf:type schema:DefinedTerm
233 Ndb522d06e08043a5b5421f6e54fb8cbf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
234 schema:name Hypertension
235 rdf:type schema:DefinedTerm
236 Ndb9a8665de71427fae03986030df8a85 rdf:first N5cbc9fd97ac74413998c335f6ea95773
237 rdf:rest N6ab5f61b71654c5b86f28c5383317e42
238 Ne0ecc0f969fa4123a4aa200daf214610 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
239 schema:name Female
240 rdf:type schema:DefinedTerm
241 Nf019ecb8bd51455687f3d972da017254 schema:name doi
242 schema:value 10.1038/hr.2011.114
243 rdf:type schema:PropertyValue
244 Nf86ee18df29b4993bcc368556c538484 schema:volumeNumber 34
245 rdf:type schema:PublicationVolume
246 Nfab3a4530a6c43ac84c50403d1b200e1 rdf:first sg:person.0624235222.83
247 rdf:rest N1f35a6910630489ebaf73e62ce1b9bff
248 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
249 schema:name Medical and Health Sciences
250 rdf:type schema:DefinedTerm
251 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
252 schema:name Cardiorespiratory Medicine and Haematology
253 rdf:type schema:DefinedTerm
254 sg:journal.1313717 schema:issn 0916-9636
255 1348-4214
256 schema:name Hypertension Research
257 schema:publisher Springer Nature
258 rdf:type schema:Periodical
259 sg:person.01012024207.33 schema:affiliation grid-institutes:grid.136593.b
260 schema:familyName Komuro
261 schema:givenName Issei
262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012024207.33
263 rdf:type schema:Person
264 sg:person.01075476751.12 schema:affiliation grid-institutes:None
265 schema:familyName Ohtsuka
266 schema:givenName Masashi
267 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075476751.12
268 rdf:type schema:Person
269 sg:person.01203207133.99 schema:affiliation grid-institutes:grid.136304.3
270 schema:familyName Narumi
271 schema:givenName Hiroya
272 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203207133.99
273 rdf:type schema:Person
274 sg:person.01371272633.17 schema:affiliation grid-institutes:grid.136304.3
275 schema:familyName Hasegawa
276 schema:givenName Hiroshi
277 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01371272633.17
278 rdf:type schema:Person
279 sg:person.016657042642.17 schema:affiliation grid-institutes:grid.136304.3
280 schema:familyName Kobayashi
281 schema:givenName Yoshio
282 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016657042642.17
283 rdf:type schema:Person
284 sg:person.0624235222.83 schema:affiliation grid-institutes:grid.136304.3
285 schema:familyName Takano
286 schema:givenName Hiroyuki
287 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624235222.83
288 rdf:type schema:Person
289 sg:pub.10.1007/s11906-005-0019-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1033309130
290 https://doi.org/10.1007/s11906-005-0019-y
291 rdf:type schema:CreativeWork
292 sg:pub.10.1038/hr.2009.131 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008963088
293 https://doi.org/10.1038/hr.2009.131
294 rdf:type schema:CreativeWork
295 sg:pub.10.1038/hr.2009.34 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047258719
296 https://doi.org/10.1038/hr.2009.34
297 rdf:type schema:CreativeWork
298 sg:pub.10.1186/1475-2840-4-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018238203
299 https://doi.org/10.1186/1475-2840-4-6
300 rdf:type schema:CreativeWork
301 sg:pub.10.1291/hypres.28.203 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026569557
302 https://doi.org/10.1291/hypres.28.203
303 rdf:type schema:CreativeWork
304 sg:pub.10.1291/hypres.28.917 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045343815
305 https://doi.org/10.1291/hypres.28.917
306 rdf:type schema:CreativeWork
307 sg:pub.10.1291/hypres.30.49 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010521145
308 https://doi.org/10.1291/hypres.30.49
309 rdf:type schema:CreativeWork
310 grid-institutes:None schema:alternateName Department of Cardiovascular Medicine, Chiba Social Insurance Hospital, Chiba, Japan
311 Department of Cardiovascular Medicine, Seirei Yokohama Hospital, Yokohama, Japan
312 schema:name Department of Cardiovascular Medicine, Chiba Social Insurance Hospital, Chiba, Japan
313 Department of Cardiovascular Medicine, Seirei Yokohama Hospital, Yokohama, Japan
314 rdf:type schema:Organization
315 grid-institutes:grid.136304.3 schema:alternateName Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan
316 Department of Frontier Japanese-Oriental ‘Kampo’ medicine, Chiba University Graduate School of Medicine, Chiba, Japan
317 schema:name Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan
318 Department of Frontier Japanese-Oriental ‘Kampo’ medicine, Chiba University Graduate School of Medicine, Chiba, Japan
319 rdf:type schema:Organization
320 grid-institutes:grid.136593.b schema:alternateName Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
321 schema:name Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
322 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...